The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

被引：7
|
作者：
Bartalucci, Niccolo
Bogani, Costanza
Martinelli, Serena
Mannarelli, Garmela
Villeval, Jean-Luc
Vannucchi, Alessandro M.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1599.1599
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1599
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Hyperglycemia in patients treated with the pan-PI3K inhibitor buparlisib (BKM120): characterization, management, and assessment for pharmacodynamics
    Azaro, A.
    Rodon, J.
    Vansteenkiste, J. F.
    Ando, Y.
    Doi, T.
    Mills, D.
    Sarr, C.
    Di Tomaso, E.
    Massacesi, C.
    Naumann, R. W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S186 - S186
  • [32] PRECLINICAL AND PRELIMINARY CLINICAL ACTIVITY OF NVP-BKM120, AN ORAL PAN-CLASS I PI3K INHIBITOR, IN THE BRAIN
    Maira, M.
    Schnell, C.
    Lollini, P.
    Chouaid, C.
    Schmid, P.
    Nanni, P.
    Lam, D.
    Di Tomaso, E.
    Massacesi, C.
    Rodon, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 537 - 537
  • [33] Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
    Saura, C.
    Burris, H.
    Arteaga, C. L.
    Mayer, I.
    Germa, C.
    Fretault, N.
    Sternberg, D.
    Trandafir, L.
    Massacesi, C.
    Rodon, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
  • [34] Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120
    Bashash, Davood
    Delshad, Mahda
    Riyahi, Niknam
    Safaroghli-Azar, Ava
    Pourbagheri-Sigaroodi, Atieh B.
    Momeny, Majid
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 841 : 10 - 18
  • [35] BKM120 and BYL719 (PI3K inhibitors) sensitize estrogen receptor positive breast cancer cells to tamoxifen
    Chen, I-Chun
    Gao, Ming
    Hsiao, Lii-Ping
    Huang, Yi-Wen
    Yu, Huei-Chieh
    Yeh, Ling-Chiun
    Cheng, Ann-Lii
    Lu, Yen-Shen
    CANCER RESEARCH, 2015, 75
  • [36] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [37] Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    Bendell, Johanna C.
    Rodon, Jordi
    Burris, Howard A.
    de Jonge, Maja
    Verweij, Jaap
    Birle, Diana
    Demanse, David
    De Buck, Stefan S.
    Ru, Qinhua C.
    Peters, Malte
    Goldbrunner, Michael
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 282 - 290
  • [38] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [39] Apoptin Overexpression Efficiently Amplified Cytotoxic Effects of PI3K Inhibition Using BKM120 in Lymphoblastic Leukemia Cell Lines
    Anjam-Najmedini, Ali
    Vahabpour, Rohollah
    Safaroghli-Azar, Ava
    Kazemi, Alireza
    Movahhed, Parvaneh
    Momeny, Majid
    Bashash, Davood
    ADVANCED PHARMACEUTICAL BULLETIN, 2022, 12 (03) : 613 - 622
  • [40] PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
    Chuang, Fu-Cheng
    Wang, Chih-Chun
    Chen, Jian-Han
    Hwang, Tzer-Zen
    Yeh, Shyh-An
    Su, Yu-Chieh
    PLOS ONE, 2021, 16 (01):
12345